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High blood pressure (hypertension) is an important risk factor for cardiovascular disease, a significant cause of 
morbidity and mortality worldwide.1 The diagnosis and man-
agement of hypertension depend on accurate measurement 
of blood pressure so that antihypertensive treatment can be 
targeted appropriately and unnecessary adverse effects and 
healthcare costs can be avoided.2 Traditionally, blood pressure 
measurement has taken place in the primary care physician’s 
office or clinic using an electronic oscillometric or aneroid 
sphygmomanometer (clinic blood pressure; Table 1), but it 
has long been recognized that home or ambulatory (out-of-
office) blood pressures provide more accurate estimates of a 
patient’s true mean blood pressure.3 This is in part because 
multiple readings are taken and it correlates with a range of 
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cardiovascular outcomes and end-organ damage better than 
clinic blood pressure.4,5
Clinic blood pressure values are often different from out-of-
office blood pressure and can lead to incorrect classification of 
blood pressure status and hence inappropriate management.6,7 
Patients with higher clinic blood pressure than the correspond-
ing out-of-office pressure will have a negative home–clinic 
blood pressure difference (white coat effect) and are at risk of 
overtreatment (Figure S1 in the online-only Data Supplement).8 
Conversely, patients with higher out-of-office blood pressures 
than the corresponding clinic blood pressure would be expected 
to have a positive home–clinic blood pressure difference (masked 
effect), and often remain unrecognized and therefore potentially 
undertreated (Figure S1).9 Such patients are at increased risk of 
target-organ damage10 and have cardiovascular morbidity and 
mortality not dissimilar to sustained hypertension.11
Strategies to reduce these misclassifications are emerg-
ing and include the use of multiple automated clinic blood 
pressure readings which have been shown to reduce the white 
coat effect.12,13 In the United States, the Preventive Services 
Task Force14 have recently released guidelines recommend-
ing that home or ambulatory blood pressure monitoring is 
used to confirm a diagnosis of hypertension, an approach 
which has already been adopted in the United Kingdom,15 
where it is considered cost-effective because of a reduction in 
misdiagnosis caused by the white coat effect.2 However, this 
approach will result in some patients with sustained hyper-
tension identified by clinic blood pressure readings being sent 
for arguably unnecessary out-of-office monitoring, which 
some patients find uncomfortable, and importantly, this strat-
egy will not capture those patients with masked hypertension.
Recent work by some of the authors has shown that the 
change in clinic blood pressure compared with multiple 
automated clinic readings from a single visit can predict the 
home–clinic blood pressure difference.16 This study aimed 
to use patient characteristics and details of repeated clinic 
blood pressure measurements to derive a model for predicting 
this home–clinic blood pressure difference. Furthermore, we 
aimed to validate this model and examine its application as a 
means to target ambulatory blood pressure monitoring more 
efficiently in routine clinical practice.
Methods
An extended version of the Methods is available in the online-only 
Data Supplement. Blood pressure definitions and terminology used 
are summarized in Table 1.
Study Design and Source Data
The present study was an individual patient data analysis of cohort 
studies conducted in a primary care setting.12,17–21 A linear regression 
model predicting the home–clinic blood pressure difference was 
derived in 2 data sets using candidate predictors identified from a 
literature review. All included studies collected relevant data includ-
ing clinic, home, and daytime ambulatory blood pressure readings, 
using a validated electronic oscillometric blood pressure monitor, 
and details of patient characteristics and medical history. The char-
acteristics of patients from included studies are detailed in Table 2. 
Individual clinic readings were available in each study permitting 
estimation of a variety of different definitions of clinic blood pres-
sure. Patients in the Conventional Versus Automated Measurement 
of Blood Pressure in the Office (CAMBO) study12 had their clinic 
blood pressure measured with a BpTRU device with either the 
doctor or nurse taking the first reading and then leaving the room 
for the remaining measurements. In all other studies, multiple clinic 
readings were taken in the presence of a nurse or practice reception 
staff.17–20 Because our study involved secondary analysis of existing 
data, it was not possible to standardize protocols for blood pressure 
measurement across studies, and specific protocols for the measure-
ment of home and daytime ambulatory blood pressures did vary to 
some degree (Table S1).
Patients were selected for the derivation cohort from the Blood 
Pressure in Ethnic groups (BP-Eth)17 and Telemonitoring and Self-
Management in the Control of Hypertension (TASMINH2)19 stud-
ies (n=991) because these were considered to be sufficiently large 
and representative of the population likely to undergo blood pressure 
monitoring for diagnosis and management of hypertension. Patients 
from the remaining 4 studies12,18,20,21 were used in the validation co-
hort (n=1172).
Statistical Analysis
Selection of Candidate Predictors
Candidate predictors considered for inclusion in the model were 
identified by literature review.22 Of the 60 identified, a total of 14 
variables were considered for inclusion in the model, including age, 
sex, body mass index, diagnosis of hypertension and time from diag-
nosis, antihypertensive prescription, smoking status, alcohol con-
sumption, diagnosis of cardiovascular disease, clinic blood pressure 
level (systolic/diastolic), and multiple clinic blood pressure charac-
teristics defined as previously described.16 These characteristics were 
the difference between the first and last clinic blood pressure reading 
(referred to as the clinic blood pressure change [estimated from 3 or 
6 readings]), the rate of the change in clinic blood pressure (referred 
Table 1. Definitions of Blood Pressure Measurements 
Described in the Present Study
Term Definition
Clinic blood 
pressure
First clinic blood pressure reading from a single 
clinic visit using an electronic oscillometric 
sphygmomanometer
Multiple clinic blood 
pressure readings
3–6 clinic blood pressure readings from a single 
clinic visit using an automated oscillometric 
sphygmomanometer
Clinic blood 
pressure change
Difference between the first and third (or sixth) 
clinic blood pressure reading taken in a single 
clinic visit using an automated oscillometric 
sphygmomanometer
Daytime ambulatory 
blood pressure
Ambulatory blood pressure measured at 15–60 
minute intervals during the daytime (definition of 
daytime and interval varies between studies)
Home blood 
pressure
Mean of 6 days of readings (2 readings per day 
taken in the morning) after discarding the first 
day’s readings
Out-of-office blood 
pressure
Daytime ambulatory blood pressure or home blood 
pressure (if daytime ambulatory blood pressure is 
not available)
Out-of-office 
hypertension
Daytime ambulatory blood pressure or home blood 
pressure ≥135/85 mm Hg
Home–clinic blood 
pressure difference
The difference between out-of-office blood 
pressure and automated blood pressure measured 
in the clinic
Model-adjusted 
clinic blood pressure
First clinic blood pressure reading added to the 
predicted home–clinic blood pressure difference 
(estimated by the PROOF-BP prediction algorithm).
PROOF-BP indicates Predicting Out-of-Office Blood Pressure in the clinic.
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to as the blood pressure slope [estimated from 3 or 6 readings]), and 
the curvature of this change in clinic blood pressure (referred to as 
the blood pressure quadratic [estimated from 6 readings]). Age, sex, 
and clinic blood pressure variables were included in the final model a 
priori because they were cited as significant predictors of white coat 
or masked hypertension in more than twice as many published stud-
ies compared with other predictors in a previous literature review.22,23 
Backward stepwise selection was used to select the remaining candi-
date predictors for the final model. Only predictors reaching a signifi-
cance level of P<0.05 were included.
Model Derivation
A complete case analysis was conducted because of low amount 
of missing data. Two separate linear regression models were con-
structed examining factors that predict the systolic and diastolic 
home–clinic blood pressure difference (the difference between the 
first clinic blood pressure reading and mean out-of-office blood 
pressure). Out-of-office blood pressure was taken to be mean day-
time ambulatory blood pressure where available; otherwise, mean 
home blood pressure was used (Table 1).19,20 Because of colinear-
ity between some of the candidate predictors listed above, separate 
models were compared in 3 stages using likelihood ratio tests. The 
best fitting model at each stage was considered in the next stage 
and where there was no significant difference in model fit, the most 
parsimonious model was selected. Stage 1 compared 5 different 
prediction models examining combinations of clinic blood pressure 
characteristic. Stage 2 compared the best fitting model from the first 
step using different definitions of clinic blood pressure (first clinic 
reading; mean of 1–3 readings; mean of 2–3 readings; mean of 1–6 
readings; or the mean of 2–6 readings). The final stage explored 
prespecified interactions of all candidate predictors with age, sex, 
and diagnosis of hypertension, and the interaction between clinic 
blood pressure and the characteristics of the change in clinic blood 
pressure. Ninety-five percent confidence intervals (CIs) for model 
coefficients were estimated with bootstrap resampling (200 repli-
cations). Model coefficients are presented for centered continuous 
variables in the final model.
Model Validation and Performance
The agreement between predicted and actual home–clinic blood 
pressure differences was examined in both derivation and valida-
tion cohorts using Pearson correlation coefficient and Bland–Altman 
plots. A model-adjusted clinic blood pressure value was calculated by 
combining the original clinic pressure (first clinic reading) with the 
home–clinic blood pressure difference estimated from the model. The 
ability of the model-adjusted clinic blood pressure to predict out-of-
office hypertension was assessed using area under the receiver opera-
tor characteristic (AUROC) curve statistics. High AUROC values 
(closer to 1) indicate better model discrimination.
Potential strategies for referral for out-of-office monitoring were 
explored in the derivation cohort (Tables S2 and S3), with the optimal 
strategy defined as a threshold which produced an overall classifica-
tion error of ≤10% with the lowest proportion of patients referred 
for out-of-office monitoring. Model performance detecting true out-
of-office hypertension was compared with existing strategies for 
blood pressure measurement described in international hypertension 
guidelines (Table S4).15,24–26 The model was also applied to a nomi-
nal population from our validation cohort, with a comparable dis-
tribution of clinic blood pressures to that documented in the Health 
Survey for England. Using this nominal population, the number of 
patients being correctly diagnosed with hypertension per 1000 indi-
viduals was compared with the current National Institute for Health 
and Care Excellence (NICE) diagnostic algorithm15 (considered best 
of the rest).
Table 2. Characteristics of Studies Used for Model Derivation and Validation
Study
Author 
(Year)
Total 
Population
Used in 
Analysis
Age 
(Mean±SD)
Sex  
(% Men) Population CHD Stroke
Diabetes 
Mellitus Hypertensive*
Years With 
High BP 
(Mean±SD)
Treatment for 
Hypertension
White Coat 
Hypertension†
Masked  
Hyper- 
tension†
BP-Eth‡ Martin  
et al17
771 771 59±10 375 (49%) Unselected 81 (11%) 33 (4%) 130 (17%) 344 (45%) 10±8 484 (63%) 83 (11%) 136 (19%)
CAMBO Myers  
et al12
555 379§ 64±10 131 (35%) Isolated  
systolic 
hypertensives
0 (0%) 0 (0%) 0 (0%) 166 (44%) 9±9 364 (96%) 52 (16%) 64 (19%)
HITS Mckinstry 
et al18
401 401 61±11 237 (59%) Uncontrolled 
hypertensives
N/A 0 (0%) 0 (0%) 379 (95%) N/A 352 (88%) 23 (6%) 42 (10%)
Oxford self-
monitoring 
study
Nunan  
et al21
203 203 56±10 107 (53%) Untreated, 
clinic BP 
≥130/80 
mm Hg
0 (0%) 0 (0%) 11 (5%) 109 (54%) 0±0 0 (0%) 67 (33%) 13 (6%)
TASMINH2‡ McManus 
et al19
527 220║ 67±9 103 (47%) Uncontrolled 
hypertensives
20 (9%) 12 (5%) 18 (8%) 172 (78%) 10±8 220 (100%) 42 (21%) 11 (5%)
TASMINH-
SR
McManus 
et al20
552 189║ 69±9 115 (61%) Uncontrolled, 
high-risk 
hypertensives
58 (31%) 30 
(16%)
81 (43%) 134 (71%) 11±9 160 (85%) 18 (10%) 53 (29%)
Hypertension defined as daytime out-of-office blood pressure (home or ambulatory monitoring) of ≥135/85 mm Hg. White coat systolic hypertension defined as a 
clinic blood pressure ≥140 mm Hg (mean of second and third readings) but an out-of-office blood pressure of <135 mm Hg. Masked systolic hypertension defined as a 
clinic blood pressure (mean of second and third readings) <140 mm Hg but an out-of-office blood pressure of ≥135 mm Hg. All percentages are given as a proportion 
of those patients with available data. BP indicates blood pressure; BP-Eth, Blood Pressure in Ethnic groups; CAMBO, Conventional Versus Automated Measurement of 
Blood Pressure in the Office; CHD, coronary heart disease; HITS, Telemonitoring-Based Service Redesign for the Management of Uncontrolled Hypertension; N/A; not 
available; TASMINH2, Telemonitoring and Self-Management in the Control of Hypertension; and TASMINH-SR, Targets and Self-Management for the Control of Blood 
Pressure in Stroke and at Risk Groups.
*Hypertensive according to home or ambulatory blood pressure monitoring.
†Defined according to systolic blood pressure.
‡Studies used for model derivation.
§Missing patients were those in the control arm (multiple clinic BP readings not taken) and those recruited from centers where complete clinic BP readings were not 
documented.
║Missing patients were those in the control arm of the trial and those with missing home BP data.
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Sensitivity analyses explored the model performance by individual 
study, predicting home or daytime ambulatory blood pressure, in pa-
tients with raised clinic blood pressure and those with controlled or 
normal clinic blood pressure. We also examined a revised diagnos-
tic strategy which does not use the Predicting Out-of-Office Blood 
Pressure (PROOF-BP) algorithm, but in which patients with a clinic 
blood pressure between 130/85 and 160/100 mm Hg were referred for 
out-of-office monitoring. All sensitivity analyses were conducted in 
the validation cohort (except those by individual study which com-
pared all available data).
All analyses were performed in STATA version 13.1 (MP paral-
lel edition, StataCorp, TX). Data are presented as proportions of the 
total study population or means with SD or 95% CIs unless otherwise 
stated. Ethical approval was given for all individual studies contribut-
ing data, but approval for secondary analysis using anonymized data 
was not required.
Results
Characteristics of the Study Cohort
Of the 2470 patients with out-of-office blood pressure mea-
surements enrolled across the 6 studies, relevant data were 
available for analysis in a total of 2163 patients (991 patients in 
the derivation cohort; 1172 patients in the validation cohort). 
Relevant data were not available in some patients enrolled in 
the CAMBO study12 because not all centers recorded the indi-
vidual automated clinic blood pressure readings required for 
this analysis (Table 2; Table S1). Characteristics of the deriva-
tion and validation cohorts were similar in terms of age, sex, 
the prevalence of systolic white coat hypertension and systolic 
masked hypertension (Table S5).
Model Derivation
Goodness-of-fit was similar between models examining 3 or 
6 clinic blood pressure readings (derivation stage 1; adjusted 
R2, 0.50–0.52) and those using different definitions of clinic 
blood pressure (derivation stage 2; adjusted R2, 0.50–0.52). 
The most parsimonious model selected at each stage was 
that which used patient characteristics along with the clinic 
blood pressure change (estimated from 3 clinic readings), 
with the first clinic reading as an estimate of clinic blood 
pressure.
The systolic masked effect (a positive home–clinic dif-
ference) was associated with male sex and a positive clinic 
blood pressure change (Figure 1). The clinic blood pressure 
change and a history of hypertension were predictive of a 
diastolic masked effect. The systolic white coat effect (nega-
tive home–clinic blood pressure difference) was associated 
with increasing clinic blood pressure only (Figure 1). The 
diastolic white coat effect was associated with increasing 
clinic blood pressure, increasing age, and increasing pulse 
pressure. The final model included significant interactions 
between age, sex, clinic blood pressure, the clinic blood 
pressure change, pulse pressure, body mass index, history of 
cardiovascular disease, presence of an antihypertensive pre-
scription, history of hypertension, and duration of hyperten-
sion. The final model (centered) coefficients are presented in 
Table 3 and the full equation is given in Figure S6.
Model Validation and Performance
The final model showed good calibration across all deriva-
tion and validation data sets (Pearson correlation, 0.62–0.80 
[systolic]; 0.48–0.80 [diastolic]; P<0.001; Figures S2 and 
S3). At the extremes of home–clinic blood pressure differ-
ence, the model was less accurate, as evidenced by the slight 
skew observed in the Bland–Altman plots (Figures S4 and 
S5), suggesting that the model underpredicts those with a 
large masked effect and overpredicts those with a large white 
coat effect.
The model was good at discriminating out-of-office 
hypertension (masked or sustained hypertension) in the der-
ivation cohort (AUROC, 0.80; 95% CI, 0.78–0.83 [systolic 
model]; 0.82; 95% CI, 0.80–0.85 [diastolic model]) and 
this discrimination was maintained in the validation cohort 
(AUROC, 0.75; 95% CI, 0.72–0.79 [systolic model]; 0.87; 
95% CI, 0.85–0.89 [diastolic model]; Figure 2). Using the 
model-adjusted clinic blood pressure, the optimal thresh-
olds for referral for out-of-office monitoring were ≥130/80 
and <145/90 mm Hg. In other words, in a model-adjusted 
blood pressure of <130/80 mm Hg, patients were confi-
dently predicted as normotensive and those with a model-
adjusted blood pressure of ≥145/90 mm Hg were considered 
hypertensive. Anyone with a model-adjusted blood pressure 
between the 2 required out-of-office measurements. Using 
Figure 1. Coefficient plot showing predictors of the systolic and 
diastolic home–clinic blood pressure difference. A, Continuous 
predictors. B, Binary predictors. All coefficients are presented 
from the model before stepwise selection. Coefficients for 
continuous variables are presented as centered values per unit 
increase. BMI indicates body mass index; BP, blood pressure; 
and CVD, cardiovascular disease.
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this model-adjusted blood pressure to triage patients for out-
of-office monitoring, 93% of cases were correctly classified 
(Table 4). This was an improvement of ≤29% compared 
with strategies recommended in current clinical guide-
lines (PROOF-BP, 93% [92% to 95%]; American Heart 
Association, 73% [70% to 75%]; Canadian Hypertension 
Education Program, 74% [71% to 77%]; European Society 
of Hypertension, 73% [70% to 75%]; NICE, 78% [76% 
to 81%]) with similar usage of out-of-office monitoring 
(PROOF-BP, 58% referred [55% to 61%] versus NICE, 
54% referred, [51% to 57%]; Table 4). In a nominal repre-
sentative population, for every 1000 people aged from 45 
to 74 years screened with the new algorithm, correct clas-
sification would be gained for 910 patients with 395 diag-
nosed as hypertensive, compared with the next best strategy 
(NICE algorithm) where 853 would be correctly classified 
and only 274 diagnosed as hypertensive. The additional 121 
diagnoses of hypertension result from the detection of those 
patients with masked hypertension.
Sensitivity Analyses
The results of the sensitivity analyses are detailed in the 
Appendix S1 (Table S6). Model performance was consis-
tent across individual studies (AUROC, 0.61–0.78 [systolic 
model]; 0.74–0.91 [diastolic model]) and the new algorithm 
resulted in better targeting of out-of-office blood pressure 
compared with a revised diagnostic strategy using clinic 
blood pressure alone to triage patients for out-of-office moni-
toring. Using the new algorithm to triage only those patients 
with raised clinic blood pressure (ie, only considering those 
patients with a potential white coat effect) resulted in correct 
classification of 94% of patients with only 45% requiring out-
of-office monitoring (Table S6).
Discussion
This study describes a clinical prediction model which 
combines patient characteristics (age, sex, body mass 
index, history of hypertension, cardiovascular disease, and 
Table 3. Linear Regression Model for Prediction of the Systolic/Diastolic Home–Clinic Blood Pressure Difference
Model Term
Prediction Model With Interaction Terms
Systolic Prediction Model Diastolic Prediction Model
β 95% CI P Value β 95% CI P Value
Age, y 0.07 −0.02 to 0.17 0.134 −0.33 −0.62 to −0.05 0.022
Sex, (men) 3.41 0.23 to 6.60 0.036 3.33 1.78 to 4.87 <0.001
Clinic blood pressure (first reading), mm Hg −0.50 −0.58 to −0.43 <0.001 −0.47 −0.51 to −0.42 <0.001
Clinic blood pressure change (readings 1–3), mm Hg 0.36 0.26 to 0.46 <0.001 0.31 0.21 to 0.42 <0.001
Body mass index, kg/m2 −0.21 −0.37 to −0.04 0.012 −0.07 −0.16 to 0.01 0.096
Previous diagnosis of hypertension (yes) −5.07 −12.15 to 2.01 0.161 −0.03 −3.55 to 3.49 0.987
Time from diagnosis of hypertension, y 0.18 0.00 to 0.35 0.053 … … …
Antihypertensive prescription (yes) 6.94 0.42 to 13.46 0.037 2.37 −1.30 to 6.04 0.206
History of cardiovascular disease (yes) … … … −0.40 −1.69 to 0.89 0.543
Pulse pressure (first reading), mm Hg −0.04 −0.13 to 0.05 0.397 −0.06 −0.09 to −0.03 <0.001
Age×clinic blood pressure −0.01 −0.01 to −0.00 0.027 … … …
Age×pulse pressure 0.01 0.00 to 0.02 0.030 … … …
Age×clinic blood pressure change … … … 0.01 0.00 to 0.02 0.014
Age×body mass index … … … 0.01 0.00 to 0.02 0.039
Age×history of cardiovascular disease … … … 0.18 0.02 to 0.33 0.023
Age×antihypertensive prescription at baseline … … … −0.13 −0.24 to −0.03 0.010
Sex×body mass index 0.30 0.01 to 0.58 0.041 … … …
Sex×time from diagnosis of hypertension −0.26 −0.50 to −0.02 0.034 … … …
Sex×antihypertensive prescription at baseline −14.74 −23.33 to −6.15 0.001 −8.00 −12.45 to −3.54 <0.001
Sex×previous diagnosis of hypertension 13.39 4.57 to 22.21 0.003 4.63 0.40 to 8.85 0.033
Constant −9.09 −11.55 to −6.64 <0.001 −6.98 −8.24 to −5.72 <0.001
β-Coefficients and 95% confidence intervals given in mm Hg. β-Coefficients for continuous variables are presented as centered values per unit increase unless 
otherwise stated. CI indicates confidence intervals.
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antihypertensive treatment) and 3 clinic blood pressure 
measurements from a single visit to accurately predict a 
patient’s out-of-office blood pressure. Used as a triaging 
tool for out-of-office monitoring, detection of hyperten-
sion or uncontrolled blood pressure was markedly improved 
from existing diagnostic and management strategies, specif-
ically including those with previously unrecognized masked 
hypertension.
Strengths and Limitations
This retrospective study used a large cohort of patients from 
6 previous studies providing a population representative of 
individuals from the United Kingdom and North America 
undergoing blood pressure measurement in primary care. 
Sensitivity analyses revealed consistent model performance 
across individual studies, suggesting that it would be effec-
tive regardless of the electronic blood pressure monitoring 
Figure 2. Area under the receiver operator characteristic curve (AUROC) analysis showing performance of systolic/diastolic blood 
pressure (sBP/dBP) prediction models for discrimination of out-of-office hypertension. A, sBP prediction model. B, dBP prediction model.
Table 4. Comparison of Model Performance With Current Clinical Practice in the Validation Cohort (n=1100)
Guideline (year)
Systolic AUC 
(95% CI)
Diastolic AUC 
(95% CI)
Hypertensive 
(True-Positive)
Normotensive 
(True-Negative)
White Coat 
Hypertensive 
(False-Positive)
Masked 
Hypertensive 
(False-Negative)
Correctly 
Classified
Referral for 
ABPM
AHA24 0.74 (0.71–0.77) 0.85 (0.83–0.87) 625 (57%) 173 (16%) 178 (16%) 124 (11%) 798 (73%) 0 (0%)
CHEP25 0.76 (0.73–0.79) 0.87 (0.85–0.89) 642 (58%) 172 (16%) 179 (16%) 107 (10%) 814 (74%) 0 (0%)
ESH26* 0.74 (0.71–0.77) 0.86 (0.84–0.88) 596 (54%) 203 (18%) 148 (13%) 151 (14%) 799 (73%) 0 (0%)
NICE15 0.73 (0.70–0.76) 0.84 (0.82–0.87) 513 (47%) 349 (32%) 2 (0.2%) 236 (21%) 862 (78%) 590 (54%)
PROOF-BP (2016) 0.75 (0.72–0.78) 0.87 (0.85–0.89) 720 (65%) 306 (28%) 45 (4%) 29 (3%) 1026 (93%) 640 (58%)
Data were from the Telemonitoring-Based Service Redesign for the Management of Uncontrolled Hypertension (HITS),18 Telemonitoring and Self-Management in the 
Control of Hypertension,20 Conventional Versus Automated Measurement of Blood Pressure in the Office (CAMBO),12 and Oxford self-monitoring studies.21 ABPM indicates 
ambulatory blood pressure monitoring; AHA, American Heart Association; AUC, area under the receiver–operator characteristic curve; CHEP, Canadian Hypertension 
Education Program; CI, confidence intervals; ESH, European Society of Hypertension; NICE, National Institute for health and Care Excellence; and PROOF-BP, Predicting 
Out-of-Office Blood Pressure in clinic tool.
*Analysis conducted in only 1098 patients because of missing data.
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device (BpTRU; Stabil-O-Graph) or measurement protocol 
used (rest period versus no rest period; nurse present dur-
ing measurement versus nurse not present; automatic read-
ings versus patient/nurse-initiated readings; 1-minute versus 
2-minute intervals between readings). It is well known that 
blood pressure measurements made under controlled condi-
tions in a research setting are not necessarily comparable with 
those made by a physician in routine clinical practice.24,27,28 
Differences occur for a variety of reasons, including the use 
of inadequate or uncalibrated devices29–31 and suboptimal 
measurement techniques.32–34 Indeed, the present algorithm 
requires 3 consecutive blood pressure readings to be taken 
at a single clinic visit and although this is recommended in 
most hypertension guidelines,15,24–26 ensuring this approach 
is adhered to in routine practice may require some education 
of physicians and nurses. Therefore, although this prediction 
model is shown to be accurate in a research setting, it is not 
guaranteed to work in routine clinical practice, and prospec-
tive validation of the PROOF-BP prediction tool in a clinical 
setting warrants further investigation.
Bland–Altman plots demonstrated that the PROOF-BP 
prediction model tends to underestimate those with a large 
masked effect and overestimate those with a large white coat 
effect. This is likely to be explained by the underlying popu-
lation in the derivation cohort which contained a higher pro-
portion of hypertensive (defined by clinic readings) patients 
on treatment (704 [71%]), a population known to have an 
exaggerated white coat effect compared with normoten-
sives (Figure S1).35 Although the model was less accurate at 
extremes of home–clinic blood pressure difference, it showed 
good performance detecting out-of-office hypertension 
around the clinical threshold (140/90 mm Hg) where the aver-
age home–clinic blood pressure difference is smaller.35
The present analyses used home blood pressure data to 
define out-of-office blood pressure, where daytime ambula-
tory measurements were not available (Table 1). Some argue 
that 24-hour ambulatory blood pressure should be used as the 
gold standard measure of blood pressure26 because it contains 
information about night-time blood pressure which includes 
additional prognostic information. However, the recent review 
by the US Preventive Services Task Force found no apparent 
difference among 24-hour, daytime, and night-time ambula-
tory blood pressure measurement protocols for prediction of 
cardiovascular outcomes,14 and a sensitivity analysis in the 
present study demonstrated no change in the accuracy of the 
PROOF-BP prediction model using home or daytime ambula-
tory readings.
Comparison With Previous Literature
Many studies have examined the association between patient 
characteristics and the home–clinic blood pressure difference, 
noting age,36–38 sex,36–39 and clinic blood pressure level,36–39 
along with anxiety,40,41 stress,42 and other factors22 as signifi-
cant independent predictors of white coat or masked hyper-
tension. The findings of the present study were consistent 
with previous literature, showing age, sex, clinic blood pres-
sure, pulse pressure, and a history of hypertension as signifi-
cant predictors of the home–clinic blood pressure difference. 
Interestingly, female sex was not a significant predictor of 
the white coat effect, although it was included a priori in the 
Figure 3. Algorithm for using the Predicting Out-of-Office Blood Pressure in clinic tool (PROOF-BP) prediction model to triage patients 
for out-of-office blood pressure monitoring. Existing strategies are based on the hypertension diagnostic pathway specified by the US 
Preventive Services Task Force and the National Institute for Health and Care Excellence. BP indicates blood pressure.
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final prediction model because this association has been well-
defined in the previous literature.36,38
Few studies have suggested a strategy for targeted use of 
out-of-office blood pressure in routine clinical practice. Myers 
et al43 and Godwin et al44 have proposed the use of multiple 
(automated) office blood pressure readings taken using the 
BpTRU device to identify patients with high normal blood 
pressure (130/80 to 139/89 mm Hg) who could be referred for 
ambulatory blood pressure to confirm the presence of masked 
hypertension. Similarly, Viera et al45 examined optimal auto-
mated clinic blood pressure levels for referral for out-of-office 
monitoring in patients with normal clinic pressure for detec-
tion of masked hypertension. However, they concluded that 
using clinic blood pressure alone was not sufficient because 
of high referral rates, and suggested that a combination of fac-
tors including patient characteristics might be more effective 
at targeting out-of-office blood pressure more efficiently.
Implications for Clinical Practice
The US Preventive Services Task Force14 recently released 
guidelines recommending that ambulatory blood pressure 
monitoring is used to confirm a diagnosis of hypertension. 
It is anticipated that these guidelines will follow a similar 
approach to that advocated in the United Kingdom by NICE, 
which does not capture those patients with masked hyperten-
sion. The present analyses propose a method for capturing 
nearly all patients with truly raised out-of-office blood pres-
sure which is likely to result in a small increase in the amount 
of out-of-office monitoring required in routine practice but 
could still be cost-effective if it reduces the present best 
practice involving indiscriminate application of ambulatory 
monitoring.2,14,15 Indeed, our sensitivity analyses show that in 
patients with raised clinic readings, the PROOF-BP prediction 
model could potentially reduce the proportion of referrals for 
daytime ambulatory monitoring by more than half to 285/629 
(45%), with nearly all patients being accurately diagnosed 
(589/629 [94%] correctly classified) and acceptable false-
positive and false-negative rates (6% and 0%, respectively). 
Importantly, this new method identifies patients with possible 
masked hypertension which is otherwise unsuspected unless 
there is evidence of unexpected end-organ damage.
An algorithm for using the PROOF-BP prediction tool in 
routine clinical practice is presented in Figure 3. Electronic 
blood pressure monitors which take 3 consecutive readings 
(at 1-minute intervals) are now cheap and routinely avail-
able, permitting use of this algorithm before, during, or 
after a standard physician consultation in primary care. The 
prediction model could easily be incorporated into general 
practice computer systems, accessed as an online calcula-
tor or even built into smartphones linked to blood pressure 
monitors to facilitate implementation in routine clinical prac-
tice. This novel approach to measurement and management 
would require buy in from both patients and practitioners and 
therefore some degree of education may be required during 
implementation.
Perspectives
The present study shows that a combination of simple patient 
characteristics with 3 clinic blood pressure measurements 
from a single visit can accurately identify those patients 
requiring out-of-office blood pressure monitoring for sus-
pected white coat hypertension and arguably most importantly 
masked hypertension. This prediction model has the poten-
tial to improve the accuracy of diagnosis and management of 
hypertension in primary care, and prospective validation in 
routine clinical practice along with analysis of cost-effective-
ness are now warranted.
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What Is New?
•	This study shows that a simple linear regression model incorporating 
patient characteristics and 3 consecutive clinic blood pressure measure-
ments from a single clinic visit can accurately identify those patients 
requiring out-of-office blood pressure monitoring for suspected white 
coat or masked hypertension.
•	The model performance was consistent across populations, and in stud-
ies using different blood pressure monitors and measurement tech-
niques, suggesting that the results are widely applicable across Primary 
Care.
What Is Relevant?
•	This prediction model could be used as an online calculator or integrated 
into practice computer systems for triaging of out-of-office monitoring to 
permit detection of those patients with white coat or masked hyperten-
sion in routine clinical practice.
•	The present analyses suggest such an approach would improve the de-
tection of hypertension and provide a strategy for capturing patients with 
apparent masked hypertension for the first time.
Summary
Our findings suggest that it is possible to predict which patients are 
most likely to display a white coat or masked effect, using patient 
characteristics and multiple clinic blood pressure measurements 
from a single clinic visit.
Novelty and Significance
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Extended methods 
Study design and source data 
The present study was an individual patient data analysis of cohort studies conducted in a 
Primary Care setting.
1-6
 A linear regression model predicting the home-clinic blood pressure 
difference was derived in two datasets using candidate predictors identified from a literature 
review. All included studies collected relevant data including clinic, home and/or daytime 
ambulatory blood pressure readings using a validated electronic oscillometric blood pressure 
monitor and details of patient characteristics and medical history. The characteristics of 
patients from included studies are detailed in table 1. Patients in the CAMBO study
5
 had their 
clinic blood pressure measured with a BpTRU device with either the doctor or nurse taking 
the first reading and then leaving the room for the remaining measurements. In all other 
studies, multiple clinic readings were taken in the presence of a nurse or practice reception 
staff.
1-4
 Individual clinic readings were available in each study permitting estimation of a 
variety of different definitions of clinic blood pressure. Since this study involved secondary 
analysis of existing data, it was not possible to standardise protocols for blood pressure 
measurement across studies and thus specific definitions of home and daytime ambulatory 
blood pressure varied to some degree (eTable 1).  
 
Patients were selected for the derivation cohort from the BP-Eth
1
 and TASMINH2
3
 studies 
(n=991) because these were considered to be sufficiently large and representative population 
of patients likely to undergo blood pressure monitoring for diagnosis and management of 
hypertension in routine clinical practice. The remaining four studies
2, 4-6
 were utilised in the 
validation cohort (n=1,172). 
 
Selection of candidate predictors 
Candidate predictors considered for inclusion in the model were identified by literature 
review.
7
 Of the 60 identified, 24 were excluded because they were not considered routinely 
available in Primary Care. A further 19 predictors were excluded due to a lack of availability 
in the datasets used. Five variables describing history of cardiovascular disease and the 
number of antihypertensive medications prescribed were simplified to the presence of 
disease/medication or not, due to missing data in some studies. In total, 14 variables were 
considered in the model derivation and comprised age (continuous), sex (male/female), body 
mass index (BMI; continuous), diagnosis of hypertension (yes/no), time since diagnosis of 
hypertension (continuous), antihypertensive prescription (yes/no), smoking status 
(current/non-smoker), alcohol consumption (yes/no), diagnosis of cardiovascular disease 
(yes/no), clinic systolic and diastolic blood pressure (continuous) and multiple clinic blood 
pressure characteristics defined as previously described.
8
 These characteristics were the 
difference between the first to last clinic blood pressure reading (‘clinic blood pressure 
change’, continuous; estimated from 3 or 6 readings), the rate of the change in clinic blood 
pressure (referred to as the ‘clinic blood pressure slope’ [continuous; estimated from 3 or 6 
readings]) and the ‘curvature’ this change in clinic blood pressure (referred to as the ‘clinic 
blood pressure quadratic’ [continuous; estimated from 6 readings]). Continuous variables 
were centred before use. Age, sex and clinic blood pressure variables were included in the 
 4 
 
final model a priori because they were cited as significant predictors of white coat or masked 
hypertension in more than twice as many published studies compared to other predictors in 
previous literature review.
7, 9
 Backwards stepwise selection was used to select the remaining 
candidate predictors for the final model. Only predictors reaching a significance level of p 
<0.05 were included.  
 
Data cleaning 
Where necessary, variables of interest were recoded to ensure consistency across datasets. 
For example, smoking status was standardised to ‘current smoker’ vs. ‘non-smoker’ with ex-
smokers classed as non-smokers where appropriate.  History of hypertension was defined as a 
documented diagnosis of hypertension prior to enrolment in a given study. This could have 
been based on clinic or out-of-office readings or a combination of both. History of 
cardiovascular disease was defined as any coronary artery disease (CHD; including 
myocardial infarction, angina or coronary artery bypass graft), stroke, peripheral vascular 
disease or heart failure. Patients enrolled in the HITS study
2
 (where presence of CHD was not 
recorded) were assumed to have no history of CHD for the purposes of model validation. 
 
Data were cleaned and outlying values were excluded where appropriate. Blood pressure 
outliers were defined a systolic blood pressure of <70mmHg or >260mmHg and a diastolic 
blood pressure of <40mmHg or >150mmHg as previously described.
10
 BMI values of zero or 
>75 were recoded to missing. Data from patients which did not appear to meet the original 
study inclusion criteria were also recoded to missing (e.g. age 7 years when inclusion criteria 
specifies age 45 and above). 
 
Model derivation 
Because data in each study were collected specifically for clinical trials or cohort studies, 
data completeness was high (>95%) in all variables of interest. Thus, a compete case analysis 
was possible and no attempt was made to impute missing data. A linear regression model was 
constructed examining factors that predicted the home-clinic blood pressure difference (1
st
 
clinic blood pressure reading minus mean out-of-office blood pressure). Out-of-office blood 
pressure was taken to be mean daytime ambulatory blood pressure where available, otherwise 
home blood pressure was used.
3, 4
 Due to co-linearity between some of the candidate 
predictors listed above, separate models were compared in three stages using likelihood ratio 
tests. The best fitting model at each stage was considered in the next stage and where there 
was no significant difference in model fit, the most parsimonious model was selected. Stage 
one compared five different prediction models examining different combinations of 
automated clinic blood pressure characteristic: 
- Model 1 = the slope and quadratic of the change in clinic blood pressure across 6 
readings;
8
  
- Model 2 = the slope of the change in clinic blood pressure across 6 readings;8   
- Model 3 = the clinic blood pressure change across 6 readings;  
- Model 4 = the slope of the change in clinic blood pressure across 3 readings;8   
- Model 5 = the clinic blood pressure change across 3 readings.  
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Stage two compared the best fitting model from the first step using different definitions of 
mean automated clinic blood pressure (1
st
 clinic reading; mean of 1-3 readings; mean of 2-3 
readings; mean of 1-6 readings; or the mean of 2-6 readings). The final stage explored pre-
specified interactions of all candidate predictors with age, sex and diagnosis of hypertension 
and the interaction between clinic blood pressure and the characteristics of the change in 
clinic blood pressure. Ninety-five percent confidence intervals (CIs) for model coefficients 
were estimated with bootstrap resampling (200 replications). Model coefficients are 
presented for centred continuous variables in the final model. 
 
Model validation and performance 
The agreement between predicted and actual home-clinic blood pressure differences was 
examined in both derivation and validation cohorts using Pearson’s correlation coefficient 
and Bland-Altman plots. The ability of the model-adjusted clinic blood pressure to predict 
out-of-office hypertension was assessed using Area Under the Receiver Operator 
Characteristic (AUROC) curve statistics. High AUROC values (up to 1) indicate better model 
discrimination. The ‘model-adjusted’ clinic blood pressure value was calculated by 
combining the original clinic pressure (1
st
 clinic reading) with the home-clinic blood pressure 
difference estimated from the model.  
 
Potential strategies for referral for out-of-office monitoring were explored in the derivation 
cohort (see appendix, eTables 2 and 3), with the optimal strategy defined as a threshold 
which produced an overall classification error of <10% with the lowest proportion of patients 
referred for out-of-office monitoring. Optimal thresholds were identified in the derivation 
cohort (prevalence of out-of-office hypertension = 46%) and examined in the validation 
cohort (prevalence of out-of-office hypertension = 68%). Model performance detecting true 
out-of-office hypertension was compared to existing strategies for blood pressure 
measurement described in international hypertension guidelines from the American Heart 
Association (AHA),
11
 Canadian Hypertension Education Programme (CHEP),
12
 European 
Society of Hypertension (ESH)
13
 and NICE
14
 (see appendix, eTable 2). The model was also 
applied to a nominal population from our validation cohort, with a comparable distribution of 
clinic blood pressures to that documented in the Health Survey for England. Using this 
nominal population, the number of patients being correctly diagnosed with hypertension per 
1,000 individuals was compared to the current NICE diagnostic algorithm
14
 (considered best 
of the rest). 
 
Sensitivity analyses explored the model performance by individual study, predicting home 
versus ambulatory blood pressure, in patients with raised clinic blood pressure and those with 
controlled or normal clinic blood pressure (clinic blood pressure of ±140/90mmHg using the 
NICE definition).
14
 In addition, model performance was compared to a revised ‘NICE’ 
diagnostic strategy in which patients with a clinic blood pressure between 130/85mmHg and 
160/100mmHg are referred for out-of-office monitoring (identified as the optimal referral 
strategy using method described above). All sensitivity analyses were conducted in the 
validation cohort (except those by individual study which compared all available datasets). 
 
 6 
 
All analyses were conducted in STATA version 13.1 (MP parallel edition, StataCorp, Texas, 
USA). Data are presented as proportions of the total study population or means with standard 
deviation or 95% CIs unless otherwise stated. Ethical approval was given for all individual 
studies contributing data but approval for secondary analysis on anonymised data was not 
required. 
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Table S1. Methods of blood pressure measurement in studies used for model derivation and validation  
Study 
Clinic BP 
monitor 
N
u
m
b
er
 o
f 
C
li
n
ic
 
re
a
d
in
g
s 
Method of clinic measurement 
O
u
t-
o
f-
o
ff
ic
e 
m
o
n
it
o
ri
n
g
 
H
o
m
e 
B
P
 
m
o
n
it
o
r 
M
in
 n
u
m
b
er
 
o
f 
H
o
m
e 
re
a
d
in
g
s 
Definition of home BP 
ABPM 
monitor 
M
in
 n
u
m
b
er
 
o
f 
A
B
P
M
 
re
a
d
in
g
s Definition of daytime 
ABPM 
BP-Eth1a BpTRU 6 
6 readings, taken at 1 minute 
intervals after 5 minutes of rest; 
nurse present 
Home 
& 
ABPM 
Omron 
705IT 
12 
Mean of 6 days of readings (2 
readings per day taken in the 
morning) after discarding the 
1st days' readings 
SpaceLabs 
90217 
14 
Readings taken between 
6:00am and 10:00pm 
CAMBO5 BpTRU 6 
6 readings taken at 2 minutes 
intervals; no rest period, patient 
left alone after 1st reading 
ABPM n/a n/a n/a 
SpaceLabs 
90207 
64 
Readings whilst patient 
was awake, documented 
in a patient diary 
HITS2 
Stabil-O-
Graph, 
SpaceLabs 
90207 
3 
BP measured once in both arms 
using the Stabil-O-Graph and 
then twice more using the 
SpaceLabs 90207 after 5 minutes 
of rest; nurse present  
Home 
& 
ABPM 
Stabil-O-
Graph 
12 
Mean of 6 days of readings (2 
readings per day taken in the 
morning) after discarding the 
1st days' readings 
SpaceLabs 
90207 
20 
Readings taken between 
6:00am and 10:00pm 
Oxford self-
monitoring 
study6 
Stabil-O-
Graph 
8 
BP measured once in both arms, 
then 6 readings taken one after 
the other in selected arm, after 5 
minutes of rest; 
nurse/receptionist present  
Home 
& 
ABPM 
Stabil-O-
Graph 
8 
Mean of 6 days of readings (2 
readings per day taken 
morning & evening) after 
discarding the 1st days' 
readings 
Microlife 
Watch BP 
03 
14 
Readings taken between 
7:00am and 11:00pm 
TASMINH23a BpTRU 6 
6 readings, taken at 1 minute 
intervals after 5 minutes of rest; 
nurse present  
Home 
Omron 
705IT 
12 
Mean of 6 days of readings (2 
readings per day taken in the 
morning) after discarding the 
1st days' readings 
n/a n/a n/a 
TASMINH-
SR4 
BpTRU 6 
6 readings, taken at 1 minute 
intervals after 5 minutes of rest; 
nurse present  
Home 
Omron 
705IT 
12 
Mean of 6 days of readings (2 
readings per day taken in the 
morning) after discarding the 
1st days' readings 
n/a n/a n/a 
a
Studies utilised for model derivation 
BP = blood pressure; ABPM = ambulatory blood pressure monitoring    
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Table S2. AUROC analyses for model adjusted systolic blood pressure thresholds for referral of ambulatory blood pressure monitoring (n=935) 
Lower/upper thresholds 
of model adjusted systolic 
blood pressure 
  
Hypertensive 
(True positive) 
Normotensive 
(True negative) 
White coat 
hypertensive 
(False positive) 
Masked 
hypertensive 
(False negative) 
Total error 
rate 
Patients 
referred for 
ABPM 
No. % No. % No. % No. % No. % No. % 
<120 mmHg >165 mmHg 1 0% 61 7% 0 0% 1 0% 1 0% 872 93% 
<120 mmHg >160 mmHg 9 1% 61 7% 0 0% 1 0% 1 0% 864 92% 
<120 mmHg >155 mmHg 21 2% 61 7% 0 0% 1 0% 1 0% 852 91% 
<120 mmHg >150 mmHg 46 5% 61 7% 6 1% 1 0% 7 1% 821 88% 
<120 mmHg >145 mmHg 110 12% 61 7% 26 3% 1 0% 27 3% 737 79% 
<125 mmHg >165 mmHg 1 0% 137 15% 0 0% 12 1% 12 1% 785 84% 
<125 mmHg >160 mmHg 9 1% 137 15% 0 0% 12 1% 12 1% 777 83% 
<125 mmHg >155 mmHg 21 2% 137 15% 0 0% 12 1% 12 1% 765 82% 
<125 mmHg >150 mmHg 46 5% 137 15% 6 1% 12 1% 18 2% 734 79% 
<125 mmHg >145 mmHg 110 12% 137 15% 26 3% 12 1% 38 4% 650 70% 
<130 mmHg >165 mmHg 1 0% 239 26% 0 0% 36 4% 36 4% 659 70% 
<130 mmHg >160 mmHg 9 1% 239 26% 0 0% 36 4% 36 4% 651 70% 
<130 mmHg >155 mmHg 21 2% 239 26% 0 0% 36 4% 36 4% 639 68% 
<130 mmHg >150 mmHg 46 5% 239 26% 6 1% 36 4% 42 4% 608 65% 
<130 mmHg >145 mmHg 110 12% 239 26% 26 3% 36 4% 62 7% 524 56% 
<135 mmHg >165 mmHg 1 0% 351 38% 0 0% 100 11% 100 11% 483 52% 
<135 mmHg >160 mmHg 9 1% 351 38% 0 0% 100 11% 100 11% 475 51% 
<135 mmHg >155 mmHg 21 2% 351 38% 0 0% 100 11% 100 11% 463 50% 
<135 mmHg >150 mmHg 46 5% 351 38% 6 1% 100 11% 106 11% 432 46% 
<135 mmHg >145 mmHg 110 12% 351 38% 26 3% 100 11% 126 13% 348 37% 
<140 mmHg >165 mmHg 1 0% 434 46% 0 0% 206 22% 206 22% 294 31% 
<140 mmHg >160 mmHg 9 1% 434 46% 0 0% 206 22% 206 22% 286 31% 
<140 mmHg >155 mmHg 21 2% 434 46% 0 0% 206 22% 206 22% 274 29% 
<140 mmHg >150 mmHg 46 5% 434 46% 6 1% 206 22% 212 23% 243 26% 
<140 mmHg >145 mmHg 110 12% 434 46% 26 3% 206 22% 232 25% 159 17% 
Area under the receiver operator characteristic = 0.80 (95% CI 0.78 to 0.83)
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Table S3. AUROC analyses for model adjusted diastolic blood pressure thresholds for referral of ambulatory blood pressure monitoring (n=935) 
Lower/upper thresholds 
of model adjusted systolic 
blood pressure 
Hypertensive 
(True positive) 
Normotensive 
(True negative) 
White coat 
hypertensive 
(False positive) 
Masked 
hypertensive 
(False negative) 
Total error 
rate 
Patients 
referred for 
ABPM 
No. % No. % No. % No. % No. % No. % 
<70 mmHg >100 mmHg 1 0% 45 5% 0 0% 1 0% 1 0% 888 95% 
<70 mmHg >85 mmHg 142 15% 45 5% 76 8% 1 0% 77 8% 671 72% 
<70 mmHg >90 mmHg 49 5% 45 5% 6 1% 1 0% 7 1% 834 89% 
<70 mmHg >95 mmHg 8 1% 45 5% 0 0% 1 0% 1 0% 881 94% 
<75 mmHg >100 mmHg 1 0% 194 21% 0 0% 6 1% 6 1% 734 79% 
<75 mmHg >85 mmHg 142 15% 194 21% 76 8% 6 1% 82 9% 517 55% 
<75 mmHg >90 mmHg 49 5% 194 21% 6 1% 6 1% 12 1% 680 73% 
<75 mmHg >95 mmHg 8 1% 194 21% 0 0% 6 1% 6 1% 727 78% 
<80 mmHg >100 mmHg 1 0% 410 44% 0 0% 43 5% 43 5% 481 51% 
<80 mmHg >85 mmHg 142 15% 410 44% 76 8% 43 5% 119 13% 264 28% 
<80 mmHg >90 mmHg 49 5% 410 44% 6 1% 43 5% 49 5% 427 46% 
<80 mmHg >95 mmHg 8 1% 410 44% 0 0% 43 5% 43 5% 474 51% 
Area under the receiver operator characteristic = 0.82 (95% CI 0.80 to 0.85) 
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Table S4. Strategy for blood pressure measurement according to guidelines 
Guideline Year Clinic blood pressure definition ABPM Threshold for hypertension 
American Heart Association 
(AHA)
11
 
2005 
Mean of the 1
st
 & 2
nd
 readings or mean of 3 if the 
initial pair of readings are >5mmHg apart 
Not routinely 
recommended 
>140/90mmHg 
Canadian Hypertension Education 
Programme (CHEP)
12
 
2014 
Mean of 2
nd
 to the 6
th
 readings taken using an 
automated blood pressure monitor 
Not routinely 
recommended >135/85mmHg 
European Society for Hypertension 
(ESH)
13
 
2013 
Mean of the 2
nd
 & 3
rd
 readings 
 
Not routinely 
recommended >140/90mmHg 
National Institute for health Clinical 
Excellence (NICE)
14a
  
2011 
Lowest of the 1 & 2
nd
 or 3
rd
 if the initial pair of 
readings are both raised 
Daytime 
>180/110mmHg (clinic) or 
>135/85mmHg (ABPM) 
PRedicting Out-of-OFfice Blood 
Pressure in the clinic algorithm 
(PROOF-BP)
b 
2015 
Adjusted clinic blood pressure using the 
PROOF-BP algorithm 
Daytime 
>145/90mmHg (adjusted 
clinic) or >135/85mmHg 
(ABPM) 
ABPM = ambulatory blood pressure monitoring 
a
Patients with raised clinic BP (>140/90 mmHg) should be referred for out-of-office monitoring (diagnosis only) 
b
Patients with an adjusted clinic BP between >130/80 and 144/89 mmHg should be referred for out-of-office monitoring 
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Table S5. Characteristics of the study population 
Characteristic Derivation cohort Validation cohort 
Total population 991 1,172 
Age (years) (mean±SD) 60±10 62±11 
Sex (male) 478 (48%) 590 (50%) 
BMI (kg/m
2
) (mean±SD) 30±6 29±6 
Smoking status (current) 125 (13%) 186 (16%) 
Diabetes (yes) 148 (15%) 92 (8%) 
History of stroke (yes) 45 (5%)  30 (3%) 
History of hypertension (yes) 701 (71%) 942 (80%) 
On treatment for hypertension (yes) 704 (71%) 876 (75%) 
Office blood pressure (mmHg) (mean±SD) 137/83±19/10 145/85±17/13 
Out-of-office blood pressure (mmHg) (mean±SD) 135/80±15/9 139/81±13/11 
White coat systolic hypertension (yes) 125 (13%) 160 (14%) 
Masked systolic hypertension (yes) 147 (16%) 172 (15%) 
BMI = body mass index; SD = standard deviation; Office blood pressure defined as the mean of the 
2
nd
 & 3
rd
 readings. White coat systolic hypertension defined as a clinic blood pressure >140mmHg 
(mean of 2
nd
 & 3
rd
 readings) but an out-of-office blood pressure of <135mmHg. Masked systolic 
hypertension defined as a clinic blood pressure (mean of 2
nd
 & 3
rd
 readings) <140mmHg but an out-
of-office blood pressure of >135mmHg
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Table S6. Sensitivity analyses 
Sensitivity analysis Total 
population 
Prevalence of 
(uncontrolled) 
hypertension† 
Systolic AUC†  
(95% CI) 
Diastolic AUC† 
(95% CI) 
True positive 
(hypertensive) 
True negative 
(normotensive) 
False positive 
(white coat 
hypertensive) 
False negative 
(masked 
hypertensive) 
Correctly 
classified† 
Referral for 
home/ 
ABPMd 
BP-Eth 715 331 (46%) 0.78 (0.75-0.81) 0.83 (0.80-0.86) 299 (42%) 368 (51%) 16 (2%) 32 (4%) 667 (93%) 423 (59%) 
CAMBO 321 137 (43%) 0.68 (0.63-0.74) 0.85 (0.80-0.91) 119 (37%) 164 (51%) 20 (6%) 18 (6%) 283 (88%) 189 (59%) 
HITS 398 376 (94%) 0.77 (0.70-0.85) 0.91 (0.89-0.94) 364 (91%) 30 (8%) 2 (0.5%) 2 (0.5%) 394 (99%) 195 (49%) 
Oxford self-monitoring 200 108 (54%) 0.73 (0.66-0.80) 0.74 (0.67-0.81) 105 (53%) 74 (37%) 18 (9%) 3 (2%) 179 (90%) 121 (61%) 
TASMINH2 220 172 (78%) 0.66 (0.57-0.75) 0.81 (0.75-0.88) 172 (78%) 37 (17%) 11 (5%) 0 (0%) 209 (95%) 144 (65%) 
TASMINH-SR 181 128 (71%) 0.61 (0.52-0.69) 0.83 (0.77-0.90) 122 (67%) 48 (27%) 5 (3%) 6 (3%) 170 (94%) 135 (75%) 
Home BPa 398 325 (82%) 0.71 (0.65-0.76) 0.84 (0.80-0.88) 323 (81%) 70 (18%) 3 (1%) 2 (1%) 393 (99%) 295 (74%) 
ABPMa 398 294 (74%) 0.77 (0.72-0.82) 0.82 (0.77-0.86) 293 (74%) 102 (26%) 2 (1%) 1 (0.3%) 395 (99%) 295 (74%) 
PROOF-BP toolb 1100 749 (68%) 0.75 (0.72-0.78) 0.87 (0.85-0.89) 720 (65%) 306 (28%) 45 (4%) 29 (3%) 1,026 (93%) 640 (58%) 
Clinic BP (revised 
thresholds)b c 
1100 749 (68%) 0.73 (0.70-0.76) 0.84 (0.82-0.87) 676 (61%) 330 (30%) 21 (2%) 73 (7%) 1006 (91%) 709 (64%) 
Patients with raised 
clinic BPb e 
629 513 (82%) 0.70 (0.65-0.75) 0.85 (0.83-0.89) 513 (82%) 76 (12%) 40 (6%) 0 (0%) 589 (94%) 285 (45%) 
Patients with controlled 
clinic BPb e 
471 236 (50%) 0.66 (0.61-0.71) 0.83 (0.79-0.87) 207 (44%) 230 (49%) 5 (1%) 29 (6%) 437 (93%) 355 (75%) 
AUC=Area Under the receiver operator characteristic Curve; CI=Confidence Intervals; ABPM=Ambulatory blood pressure monitoring; BP=blood pressure
 
a
Data from the HITS
2
 and Oxford self-monitoring studies (combined);  
b
Data from validation cohort - HITS,
2
 TASMINH-SR,
4
 CAMBO
5
 and Oxford self-monitoring study;
6
  
c
Revised referral thresholds defined as a clinic blood pressure between 130/85mmHg and 160/100mmHg 
d
For detection of out-of-office hypertension (>135/85mmHg) 
e
Clinic blood pressure >140/90mmHg 
f
Clinic blood pressure <140/90mmHg 
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Figure S1. Definitions of normotension, hypertension and the home-clinic blood pressure difference 
BP =Blood pressure; Out-of-office blood pressure may be defined by home or daytime ambulatory blood 
pressure measurements. 
Individuals with a white coat effect (negative home-clinic difference) may be normotensive, hypertensive or 
white coat hypertensive. Those with a masked effect (positive home-clinic difference) may be normotensive, 
hypertensive or masked hypertensive. Those with an out-of-office >135/85mmHg (hypertension) may be 
masked or sustained hypertensives. 
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Figure S2. Graphs showing model calibration in derivation (BP-Eth, TASMINH2) & validation (Oxford 
self-monitoring study, CAMBO, HITS, TASMINH-SR) datasets for prediction of systolic blood pressure. 
BP = Blood pressure; BP-Eth=Blood pressure in 
different Ethnic groups; TASMINH2 = 
Telemonitoring And Self-Management In 
Hypertension 2; TASMINH-SR = Telemonitoring 
And Self-Management In Hypertension in Stroke 
and at Risk groups; HITS = Telemonitoring-based 
service redesign for the management of 
uncontrolled hypertension; CAMBO = 
Conventional vs. Automated Measurement of 
Blood pressure in the Office 
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Figure S3. Graphs showing model calibration in derivation (BP-Eth, TASMINH2) & validation (Oxford 
self-monitoring study, CAMBO, HITS, TASMINH-SR) datasets for prediction of diastolic blood pressure. 
BP = Blood pressure; BP-Eth=Blood pressure in 
different Ethnic groups; TASMINH2 = 
Telemonitoring And Self-Management In 
Hypertension 2; TASMINH-SR = Telemonitoring 
And Self-Management In Hypertension in Stroke 
and at Risk groups; HITS = Telemonitoring-based 
service redesign for the management of 
uncontrolled hypertension; CAMBO = 
Conventional vs. Automated Measurement of 
Blood pressure in the Office 
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Figure S4. Bland-Altman plots showing agreement between actual & predicted home-clinic systolic blood 
pressure differences in derivation (BP-Eth, TASMINH2) & validation (Oxford self-monitoring study, 
CAMBO, HITS, TASMINH-SR) datasets
 
BP = Blood pressure; BP-Eth=Blood pressure in 
different Ethnic groups; TASMINH2 = 
Telemonitoring And Self-Management In 
Hypertension 2; TASMINH-SR = Telemonitoring 
And Self-Management In Hypertension in Stroke 
and at Risk groups; HITS = Telemonitoring-based 
service redesign for the management of 
uncontrolled hypertension; CAMBO = 
Conventional vs. Automated Measurement of 
Blood pressure in the Office 
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Figure S5. Bland-Altman plots showing agreement between actual & predicted home-clinic diastolic blood 
pressure differences in derivation (BP-Eth, TASMINH2) & validation (Oxford self-monitoring study, 
CAMBO, HITS, TASMINH-SR) datasets 
BP = Blood pressure; BP-Eth=Blood pressure in 
different Ethnic groups; TASMINH2 = 
Telemonitoring And Self-Management In 
Hypertension 2; TASMINH-SR = Telemonitoring 
And Self-Management In Hypertension in Stroke 
and at Risk groups; HITS = Telemonitoring-based 
service redesign for the management of 
uncontrolled hypertension; CAMBO = 
Conventional vs. Automated Measurement of 
Blood pressure in the Office 
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Figure S6. Final model equations 
 
  
 
  
 
sBP=systolic blood pressure; dBP=diastolic blood pressure; BMI=body mass index 
Binary variables coded as yes (1) or no (0) 
ß coefficients given for continuous explanatory variables which have not been centred. 
 
